CompletedPHASE2, PHASE3NCT01301924

Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis

Studying Leishmaniasis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Oswaldo Cruz Foundation
Principal Investigator
Armando O. Schubach, MD, PhD
IPEC/FIOCRUZ
Intervention
Meglumine antimoniate(drug)
Enrollment
72 enrolled
Eligibility
13 years · All sexes
Timeline
20082017

Study locations (1)

Collaborators

Rio de Janeiro State Research Supporting Foundation (FAPERJ) · Conselho Nacional de Desenvolvimento Científico e Tecnológico

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01301924 on ClinicalTrials.gov

Other trials for Leishmaniasis

Additional recruiting or active studies for the same condition.

See all trials for Leishmaniasis

← Back to all trials